Charlotte Grayson-Mathis, MD
Internal Medicine · Fayetteville, GANPI 1497779391
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,474 of the $4,118 with a category attached, or 60.1%. 17 manufacturers reported payments, led by Modernatx, Inc. at 56.1% of the total. Reporting peaked in 2024 at $2,334 and has fallen 90.2% since, to $228 in 2025.
Across 50 payments — averaging $82.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$2K
- Boehringer Ingelheim International GmbH$1K
- Novo Nordisk$111
- Astellas Pharma US Inc$100
- Boehringer Ingelheim$51
- Johnson & Johnson$40
- plus $245 from 11 others
Across 431 payments — averaging $22,253 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$7.2M
- Boehringer Ingelheim$1.3M
- Vertex$591K
- Merck$241K
- Genentech, Inc.$101K
- AstraZeneca$74K
- plus $92K from 5 others
What the payments were for
- Travel & lodging$2,47460%
- Food & beverage$1,54437%
- Education$1002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 16 | $2,310 |
| Boehringer Ingelheim International GmbH | 11 | $1,260 |
| Novo Nordisk | 5 | $111 |
| Astellas Pharma US Inc | 1 | $100 |
| Boehringer Ingelheim | 2 | $51 |
| Johnson & Johnson | 2 | $40 |
| Abbott | 2 | $39 |
| GSK | 2 | $34 |
| Novartis | 1 | $25 |
| Lilly USA, LLC | 1 | $24 |
| Merck | 1 | $24 |
| Medtronic | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Amgen | 1 | $18 |
| AbbVie | 1 | $14 |
| Seqirus USA Inc | 1 | $14 |
| Mannkind Corporation | 1 | $13 |
How this compares
$4,118 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 226 | $299,191 |
| JanuviaSitagliptin Phosphate | 136 | $121,853 |
| JardianceEmpagliflozin | 94 | $119,298 |
| MounjaroTirzepatide | 91 | $113,438 |
| EliquisApixaban | 104 | $104,532 |
| ProliaDenosumab | 50 | $86,002 |
| TrulicityDulaglutide | 50 | $69,735 |
| TradjentaLinagliptin | 46 | $59,664 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $50,228 |
| Repatha SureclickEvolocumab | 50 | $38,210 |
| MyrbetriqMirabegron | 50 | $37,515 |
| RexultiBrexpiprazole | 15 | $23,172 |
| LinzessLinaclotide | 21 | $22,458 |
| XareltoRivaroxaban | 21 | $21,399 |
| FarxigaDapagliflozin Propanediol | 24 | $21,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $111 | $299,191226 claims |
| Lilly USA, LLCMounjaro, Trulicity | $24 | $183,173141 claims |
| Boehringer IngelheimJardiance, Tradjenta | $51 | $178,962140 claims |
| MerckJanuvia, Janumet Xr | $24 | $140,897153 claims |
| AmgenProlia | $18 | $86,00250 claims |
| GSKTrelegy Ellipta | $34 | $50,22849 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $37,51550 claims |
| AbbVieLinzess, Synthroid | $14 | $25,42666 claims |
| Johnson & JohnsonXarelto | $40 | $21,39921 claims |
| NovartisEntresto | $25 | $12,40913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Fayetteville
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.